CUMBERLAND PHARMACEUTICALS INC
CPIXNasdaq
$6.84
↓ -10.7%Jul 17 close · end-of-day
Price
1Y↑ +76.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$102.3M
Enterprise Value
$91.3M
P/E
—
P/S
2.4
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
1.3%
Dividend Yield
—
Revenue (TTM)
$41.9M
Net Income (TTM)
-$7.4M
Free Cash Flow (TTM)
$1.4M
Gross Margin
—
Operating Margin
-17.2%
Net Margin
-17.6%
ROE
-34.1%
ROIC
-53.6%
Debt / Equity
—
Net Cash
$11.0M
Return 1Y
+84.4%
Company profile
Cumberland Pharmaceuticals Inc. focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol and Vibativ.
- CEO
- A. J. Kazimi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Tennessee
- Website
- cumberlandpharma.com
Earnings
CPIX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$9.1M↓ -22.0%
Diluted EPS-$0.22↓ -375.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.4M | -$7.7M | -$5.7M | -$9.6M | -$6.4M | -$2.8M |
| Net income | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| Diluted EPS | -$0.22 | -$0.24 | -$0.38 | -$0.44 | -$0.46 | -$0.19 |
| Operating cash flow | $5.4M | $6.3M | $8.5M | $6.1M | -$612,186.00 | $4.9M |
| Free cash flow | $5.3M | $6.2M | $8.4M | $5.8M | -$678,647.00 | $4.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -17.0% | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Net margin | -8.9% | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $9.1M | $10.4M | $11.7M | $10.8M | $8.3M | $13.7M | $9.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.0M | -$1.7M | -$1.8M | $1.3M | -$747,478.00 | -$2.0M | -$1.4M | -$3.1M |
| Net income | -$1.1M | -$1.5M | -$1.9M | $1.3M | -$740,740.00 | -$1.9M | -$1.4M | -$3.3M |
| Diluted EPS | -$0.08 | -$0.11 | -$0.14 | $0.08 | -$0.05 | -$0.13 | -$0.09 | -$0.22 |
| Operating cash flow | -$855,660.00 | $475,503.00 | $1.9M | $3.9M | $843,801.00 | $187,180.00 | $3,024.00 | $387,025.00 |
| Free cash flow | -$862,838.00 | $460,124.00 | $1.9M | $3.9M | $817,315.00 | $163,392.00 | $3,023.00 | $387,025.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -10.4% | -18.6% | -17.7% | 11.0% | -6.9% | -23.7% | -10.0% | -34.3% |
| Net margin | -11.0% | -17.0% | -18.2% | 10.7% | -6.8% | -23.4% | -10.3% | -36.0% |
Company news
Jul 1, 2026
Jun 26, 2026
- 24d agoSector Update: Healthcare Stocks Gain Late Afternoonfinance.yahoo.com
- 24d agoSector Update: Healthcare Stocks Gain Friday Afternoonfinance.yahoo.com
- 24d agoCumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conferencefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-18 | Krogulski Kenneth | Award | 4,000 | $2.80 | $11,200.00 | filing |
| 2026-03-18 | Galante Joseph C | Award | 1,800 | $2.80 | $5,040.00 | filing |
| 2026-03-18 | Brown Martin S JR | Award | 1,800 | $2.80 | $5,040.00 | filing |
| 2026-03-18 | Jones James | Award | 1,800 | $2.80 | $5,040.00 | filing |
| 2026-03-18 | Krogulski Kenneth | Award | 1,800 | $2.80 | $5,040.00 | filing |
| 2026-03-18 | Young Caroline | Award | 1,800 | $2.80 | $5,040.00 | filing |
| 2026-03-16 | KAZIMI A J· Chairman and CEO | Tax withholding | 5,845 | $3.06 | $17,885.70 | filing |
| 2025-12-31 | Krogulski Kenneth | L | 62 | $3.91 | $242.42 | filing |
| 2025-12-31 | Jones James | L | 7 | $3.91 | $27.37 | filing |
| 2025-12-31 | KAZIMI A J· Chairman and CEO | L | 7 | $3.91 | $27.37 | filing |
| 2025-12-31 | Young Caroline | L | 5 | $3.91 | $19.55 | filing |
| 2025-12-30 | Krogulski Kenneth | L | 54 | $3.94 | $212.76 | filing |
| 2025-12-30 | KAZIMI A J· Chairman and CEO | L | 8 | $3.94 | $31.52 | filing |
| 2025-12-30 | Jones James | L | 8 | $3.94 | $31.52 | filing |
| 2025-12-30 | Young Caroline | L | 2 | $3.94 | $7.88 | filing |
| 2025-12-29 | Krogulski Kenneth | L | 54 | $4.01 | $216.54 | filing |
| 2025-12-29 | Jones James | L | 8 | $4.01 | $32.08 | filing |
| 2025-12-29 | KAZIMI A J· Chairman and CEO | L | 8 | $4.01 | $32.08 | filing |
| 2025-12-29 | Young Caroline | L | 2 | $4.01 | $8.02 | filing |
| 2025-12-26 | Krogulski Kenneth | L | 54 | $4.21 | $227.34 | filing |
| 2025-12-26 | Jones James | L | 8 | $4.21 | $33.68 | filing |
| 2025-12-26 | KAZIMI A J· Chairman and CEO | L | 8 | $4.21 | $33.68 | filing |
| 2025-12-26 | Young Caroline | L | 2 | $4.21 | $8.42 | filing |
| 2025-12-24 | Krogulski Kenneth | L | 54 | $4.26 | $230.04 | filing |
| 2025-12-24 | Jones James | L | 8 | $4.26 | $34.08 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.